Literature DB >> 10596912

Lack of p21waf1 and p27kip1 protein induction by interferon-alpha2a in human melanoma cell lines.

A Bearzatto1, L Orlandi, C De Marco, M G Daidone, N Zaffaroni.   

Abstract

The ability of human recombinant interferon-alpha2a (IFNalpha2a) to induce the expression of cyclin-dependent kinase inhibitors p21waf1 and p27kip1 consequent to signal transducers and activators of transcription (STAT) protein activation was investigated in six human melanoma cell lines with different susceptibilities to the antiproliferative effect of the cytokine. All the cell lines expressed IFNalpha and IFNalpha/beta receptors. Exposure for 24 h to IFNalpha2a markedly enhanced the nuclear expression of STAT1 and STAT2 proteins in all the cell lines. However, no induction of p21waf1 or p27kip1 was consistently observed. Overall, results from the study suggest that the induction of such cyclin-dependent kinase inhibitors is not a major mechanism for the antiproliferative effect of IFNalpha2a, at least in human melanoma cell lines.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10596912     DOI: 10.1097/00008390-199910000-00005

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  2 in total

1.  Enhanced anti-melanoma efficacy of interferon α-2b via overexpression of ING4 by enhanced Fas/FasL-mediated apoptosis.

Authors:  Limin Cai; Jing Liu; Yu Wang; Hongxiao Chen; Yanli Ma; Yanhua Wang; Yongchen Wang
Journal:  Oncol Lett       Date:  2018-04-18       Impact factor: 2.967

2.  IFN-alpha and bortezomib overcome Bcl-2 and Mcl-1 overexpression in melanoma cells by stimulating the extrinsic pathway of apoptosis.

Authors:  Gregory B Lesinski; Ene T Raig; Kristan Guenterberg; Lloyd Brown; Michael R Go; Nisha N Shah; Adrian Lewis; Megan Quimper; Erinn Hade; Gregory Young; Abhik Ray Chaudhury; Katherine J Ladner; Denis C Guttridge; Page Bouchard; William E Carson
Journal:  Cancer Res       Date:  2008-10-15       Impact factor: 12.701

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.